Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.


Type
Private
HQ
Cambridge, US
Size (employees)
628 (est)+4%
Moderna Therapeutics is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Moderna Therapeutics

Stephane Bancel

Stephane Bancel

CEO
Lorence Kim

Lorence Kim

CFO
Stephen Hoge

Stephen Hoge

President
Noubar Afeyan

Noubar Afeyan

Chairman & Co-Founder
Tal Zaks

Tal Zaks

Chief Medical Officer
Steve Harbin

Steve Harbin

SVP of Human Resources & Clinical Supply Operations
Show more

Moderna Therapeutics Office Locations

Moderna Therapeutics has offices in Huntington, Chicago, Norwood, Cambridge and in 1 other location
Cambridge, US (HQ)
320 Bent St
Cambridge, US
NE47 500 Technology Square
Cambridge, US
200 Technology Square
Huddinge, SE
Hälsovägen 7-9
Show all (7)
Report incorrect company information

Moderna Therapeutics Financials and Metrics

Summary Metrics

Moderna Therapeutics's latest funding round in February 2018 was reported to be $500 m. In total, Moderna Therapeutics has raised $1.7 b. Moderna Therapeutics's latest valuation is reported to be $7.5 b.

Moderna Therapeutics Financials

USD

Revenue (Jun, 2016)

36 m

Market valuation

7.5 b
USDJun, 2016

Revenue

36 m
USDY, 2016

Revenue/Employee

99.4 k
Show all financial metrics

Moderna Therapeutics Operating Metrics

Moderna Therapeutics's Patent Applications was reported to be 250 in May, 2017.
Y, 2015May, 2017

Drugs in Development

92

Patent Applications

250
Show all operating metrics
Report incorrect company information

Moderna Therapeutics News and Updates

Moderna Therapeutics racks up $500 mln

Cambridge, Massachusetts-based Moderna Therapeutics, a developer of messenger RNA therapeutics and vaccines, has raised $500 million in funding. The investors include a subsidiary of the Abu Dhabi Investment Authority, EDBI, Sequoia Capital China, Fidelity Management & Research Company, Pictet, …
Report incorrect company information